Oncolytics Biotech Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: geoffb_si who wrote (63)	4/17/2002 9:43:20 AM
From: geoffb_si	Read Replies (1) of 103

Oncolytics gets approval from Health Canada to start Reolysin phase I/II [Glio] Thursday Apr 11 2002 News Release Dr. Matt Coffey reports Oncolytics Biotech has received approval from Health Canada to initiate a phase I/II clinical trial to investigate the use of Reolysin as a treatment for patients with recurrent malignant glioma, the most aggressive form of brain cancer. "Preclinical studies of Reolysin have shown tumour regression and survival benefits in animal models of this persistent disease," said Dr. Brad Thompson, president and chief executive officer of Oncolytics. "Based on the positive results from our recently concluded phase I trial, we are continuing with our plans to pursue further expansion of our clinical trial program in 2002. We intend to develop Reolysin as quickly as possible on the basis of a carefully planned and executed series of clinical programs." In the dose escalation or phase I portion of the phase I/II trial, patients with a variety of recurrent malignant gliomas will be enrolled. In the phase II portion of the trial, patients with recurrent glioblastoma multiforme, the most aggressive glioma, will be treated with dosages determined by the results of the dose escalation study. A total of up to 40 patients are expected to be enrolled. Malignant brain tumours occur in approximately 40,000 patients in North American and Europe each year. The standard treatment for patients with newly diagnosed malignant gliomas is surgery, followed by radiation therapy and occasionally systemic chemotherapy. However, the probability of tumour recurrence is high. Treatment options for patients with the recurrent disease are limited to additional surgery that may be combined with local chemotherapy. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 2002 Canjex Publishing Ltd. canada-stockwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next